You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

188 Results
Drug
Other Name(s): Imbruvica®
Dec 1969
Drug
Other Name(s): Bosulif®
Nov 2024
Drug
Other Name(s): Zykadia™
Nov 2024
Drug
Other Name(s): Zydelig™
Dec 1969
Drug
Other Name(s): Cotellic™
Nov 2024
Drug
Other Name(s): Lenvima®
Sep 2023
Drug
Other Name(s): Ibrance™
Dec 1969
Drug
Other Name(s): Venclexta®
Dec 1969
Drug
Other Name(s): Rydapt®
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Oct 2020
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Mar 2023

Pages